New and emerging therapies and targets: Beta-3 agonists

Handbook of Experimental Pharmacology

Volumn 243, Issue , 2017, Pages 205-223

  Michel, Lauriane Y M ^a   Balligand, Jean Luc ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Adrenergic receptor; Catecholamines; Heart failure; Hypertrophy; Nitric oxide; Remodeling

Indexed keywords

ANTIOXIDANT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE DERIVATIVE; MIRABEGRON; NITRIC OXIDE; ACETANILIDE DERIVATIVE; CATECHOLAMINE; THIAZOLE DERIVATIVE;

BETA ADRENERGIC STIMULATION; CARDIAC MUSCLE CELL; CARDIOVASCULAR EFFECT; CARDIOVASCULAR TISSUE; CATECHOLAMINE SYNTHESIS; CIRCULATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PATHOPHYSIOLOGY;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; CATECHOLAMINES; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; NITRIC OXIDE; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION; THIAZOLES; VENTRICULAR REMODELING;

EID: 85020667403     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2016_88     Document Type: Chapter

References (88)

1. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI (2004) Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110:1083–1090. doi:10.1161/01.CIR.0000139844.15045.F9
2. Amour J, Loyer X, Le Guen M, Mabrouk N, David JS, Camors E, Carusio N, Vivien B, Andriantsitohaina R, Heymes C, Riou B (2007) Altered contractile response due to increased beta3-adrenoceptor stimulation in diabetic cardiomyopathy: the role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology 107:452–460. doi:10.1097/01.anes.0000278909.40408.24
3. Angelone T, Filice E, Quintieri AM, Imbrogno S, Recchia A, Pulera E, Mannarino C, Pellegrino D, Cerra MC (2008) Beta3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway. Acta Physiol (Oxf) 193:229–239. doi:10.1111/j.1748-1716.2008.01838.x
4. Aragon JP, Condit ME, Bhushan S, Predmore BL, Patel SS, Grinsfelder DB, Gundewar S, Jha S, Calvert JW, Barouch LA, Lavu M, Wright HM, Lefer DJ (2011) Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation. J Am Coll Cardiol 58:2683–2691. doi:10.1016/j.jacc.2011.09.033
5. Ayers K, Byrne LM, DeMatteo A, Brown NJ (2012) Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59:893–898. doi:10.1161/HYPERTENSIONAHA.111.189589
6. Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Gotz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL (2014) Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 129:451–462. doi:10.1161/CIRCULATIONAHA.113.004940
7. Bristow MR (2000) Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101:558–569
8. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergicreceptor density in failing human hearts. N Engl J Med 307:205–211. doi:10.1056/NEJM198207223070401
9. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM (1990) Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82:112–125
10. Brodde OE (1991) Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43:203–242
11. Brodde OE (1993) Beta-adrenoceptors in cardiac disease. Pharmacol Ther 60:405–430
12. Bundgaard H, Liu CC, Garcia A, Hamilton EJ, Huang Y, Chia KK, Hunyor SN, Figtree GA, Rasmussen HH (2010) Beta(3) adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation 122:2699–2708. doi:10.1161/CIRCULATIONAHA.110.964619
13. Calvert JW, Condit ME, Aragon JP, Nicholson CK, Moody BF, Hood RL, Sindler AL, Gundewar S, Seals DR, Barouch LA, Lefer DJ (2011) Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 108:1448–1458. doi:10.1161/CIRCRESAHA.111.241117
14. Candelore MR, Deng L, Tota LM, Kelly LJ, Cascieri MA, Strader CD (1996) Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant. Endocrinology 137:2638–2641. doi:10.1210/endo.137.6.8641219
15. Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP (2001) Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium. Circ Res 89:599–606
16. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, Crow MT (2000) The beta(2)- adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)- dependent coupling to phosphatidylinositol 30-kinase. Circ Res 87:1172–1179
17. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK (1999) Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 274:16694–16700
18. Chu G, Lester JW, Young KB, Luo W, Zhai J, Kranias EG (2000) A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to betaagonists. J Biol Chem 275:38938–38943. doi:10.1074/jbc.M004079200
19. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509–1517. doi:10.1056/NEJMoa0810780
20. Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elia E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM (2015) Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab 21:33–38. doi:10.1016/j.cmet.2014.12.009
21. Daaka Y, Luttrell LM, Lefkowitz RJ (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88–91. doi:10.1038/36362
22. Danielsen W, v der Leyen H, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Doring V, Kalmar P (1989) Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 14:171–173
23. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW II, Kranias EG (2001) Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103:889–896
24. de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R (2008) Relation of Trp64Arg polymorphism of beta 3-adrenergic receptor gene to adipocytokines and fat distribution in obese patients. Ann Nutr Metab 52:267–271. doi:10.1159/000144047
25. Dessy C, Balligand JL (2010) Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol 59:135–163. doi:10.1016/S1054-3589(10)59005-7
26. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL (2004) Endothelial beta3- adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 110:948–954. doi:10.1161/01.CIR.0000139331.85766.AF
27. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frerart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL (2005) Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112:1198–1205. doi:10.1161/CIRCULATIONAHA.104.532960
28. Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM (2001) The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 50:455–461
29. Donckier JE, Massart PE, Van Mechelen H, Heyndrickx GR, Gauthier C, Balligand JL (2001) Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 31:681–689
30. Dumas M, Dumas JP, Bardou M, Rochette L, Advenier C, Giudicelli JF (1998) Influence of betaadrenoceptor agonists on the pulmonary circulation. Effects of a beta3-adrenoceptor antagonist, SR 59230A. Eur J Pharmacol 348:223–228
31. Edwards G, Feletou M, Weston AH (2010) Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 459:863–879. doi:10.1007/s00424-010-0817-1
32. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (1989) Molecular characterization of the human beta 3-adrenergic receptor. Science 245:1118–1121
33. Engelhardt S, Bohm M, Erdmann E, Lohse MJ (1996) Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 27:146–154. doi:10.1016/0735-1097(95)00425-4
34. Eschenhagen T (1993) G proteins and the heart. Cell Biol Int 17:723–749. doi:10.1006/cbir.1993.1135
35. Fatima T, Altaf S, Phipps-Green A, Topless R, Flynn TJ, Stamp LK, Dalbeth N, Merriman TR (2016) Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout. Rheumatol Int 36:255–261. doi:10.1007/s00296-015-3370-6
36. Feldman MD, Alderman JD, Aroesty JM, Royal HD, Ferguson JJ, Owen RM, Grossman W, McKay RG (1988) Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 82:1661–1669. doi:10.1172/JCI113778
37. Garcia-Prieto J, Garcia-Ruiz JM, Sanz-Rosa D, Pun A, Garcia-Alvarez A, Davidson SM, Fernandez-Friera L, Nuno-Ayala M, Fernandez-Jimenez R, Bernal JA, Izquierdo-Garcia JL, Jimenez-Borreguero J, Pizarro G, Ruiz-Cabello J, Macaya C, Fuster V, Yellon DM, Ibanez B (2014) Beta3 adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes. Basic Res Cardiol 109:422. doi:10.1007/s00395-014-0422-0
38. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H (1996) Functional beta3- adrenoceptor in the human heart. J Clin Invest 98:556–562. doi:10.1172/JCI118823
39. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, Balligand JL, Le Marec H (1998) The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102:1377–1384. doi:10.1172/JCI2191
40. Gauthier C, Tavernier G, Trochu JN, Leblais V, Laurent K, Langin D, Escande D, Le Marec H (1999) Interspecies differences in the cardiac negative inotropic effects of beta(3)- adrenoceptor agonists. J Pharmacol Exp Ther 290:687–693
41. Gauthier C, Langin D, Balligand JL (2000) Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21:426–431
42. He JQ, Balijepalli RC, Haworth RA, Kamp TJ (2005) Crosstalk of beta-adrenergic receptor subtypes through Gi blunts beta-adrenergic stimulation of L-type Ca2+ channels in canine heart failure. Circ Res 97:566–573. doi:10.1161/01.RES.0000181160.31851.05
43. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes – characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369:151–159. doi:10.1007/s00210-003-0860-y
44. Idigo WO, Reilly S, Zhang MH, Zhang YH, Jayaram R, Carnicer R, Crabtree MJ, Balligand JL, Casadei B (2012) Regulation of endothelial nitric-oxide synthase (NOS) S-glutathionylation by neuronal NOS: evidence of a functional interaction between myocardial constitutive NOS isoforms. J Biol Chem 287:43665–43673. doi:10.1074/jbc.M112.412031
45. Imbrogno S, Gattuso A, Mazza R, Angelone T, Cerra MC (2015) Beta3-AR and the vertebrate heart: a comparative view. Acta Physiol (Oxf) 214:158–175. doi:10.1111/apha.12493
46. Ishikawa Y, Sorota S, Kiuchi K, Shannon RP, Komamura K, Katsushika S, Vatner DE, Vatner SF, Homcy CJ (1994) Downregulation of adenylylcyclase types V and VI mRNA levels in pacinginduced heart failure in dogs. J Clin Invest 93:2224–2229. doi:10.1172/JCI117219
47. Karimi Galougahi K, Liu CC, Garcia A, Fry NA, Hamilton EJ, Figtree GA, Rasmussen HH (2015) Beta3-adrenoceptor activation relieves oxidative inhibition of the cardiac Na+-K+ pump in hyperglycemia induced by insulin receptor blockade. Am J Physiol Cell Physiol 309:C286–C295. doi:10.1152/ajpcell.00071.2015
48. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homcy CJ, Vatner SF, Vatner DE (1993) Myocardial beta-adrenergic receptor function during the development of pacinginduced heart failure. J Clin Invest 91:907–914. doi:10.1172/JCI116312
49. Komajda M, Lam CS (2014) Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35:1022–1032. doi:10.1093/eurheartj/ehu067
50. Kou R, Michel T (2007) Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J Biol Chem 282:32719–32729. doi:10.1074/jbc.M706815200
51. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA (2009) Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 104:87–94. doi:10.1161/CIRCRESAHA.108.184408
52. Lefkowitz RJ, Haber E, O’Hara D (1972) Identification of the cardiac beta-adrenergic receptor protein: solubilization and purification by affinity chromatography. Proc Natl Acad Sci U S A 69:2828–2832
53. Liggett SB, Freedman NJ, Schwinn DA, Lefkowitz RJ (1993) Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. Proc Natl Acad Sci U S A 90:3665–3669
54. Lim SL, Lam CS, Segers VF, Brutsaert DL, De Keulenaer GW (2015) Cardiac endotheliummyocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J 36:2050–2060. doi:10.1093/eurheartj/ehv132
55. Lobysheva II, Biller P, Gallez B, Beauloye C, Balligand JL (2013) Nitrosylated hemoglobin levels in human venous erythrocytes correlate with vascular endothelial function measured by digital reactive hyperemia. PLoS One 8:e76457. doi:10.1371/journal.pone.0076457
56. Longabaugh JP, Vatner DE, Vatner SF, Homcy CJ (1988) Decreased stimulatory guanosine triphosphate binding protein in dogs with pressure-overload left ventricular failure. J Clin Invest 81:420–424. doi:10.1172/JCI113335
57. Longhurst JC (1990) Coronary arteriolar vasoconstriction in myocardial ischaemia: reflexes, sympathetic nervous system, catecholamines. Eur Heart J 11(Suppl B):43–52
58. Mahata SK, Zheng H, Mahata S, Liu X, Patel KP (2016) Effect of heart failure on catecholamine granule morphology and storage in chromaffin cells. J Endocrinol 230:309–323. doi:10.1530/JOE-16-0146
59. Maier LS (2009) A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol 54:279–286. doi:10.1097/FJC.0b013e3181a1b9e7
60. Malik SG, Saraswati MR, Suastika K, Trimarsanto H, Oktavianthi S, Sudoyo H (2011) Association of beta3-adrenergic receptor (ADRB3) Trp64Arg gene polymorphism with obesity and metabolic syndrome in the Balinese: a pilot study. BMC Res Notes 4:167. doi:10.1186/1756-0500-4-167
61. Manning CD, McLaughlin MM, Livi GP, Cieslinski LB, Torphy TJ, Barnette MS (1996) Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J Pharmacol Exp Ther 276:810–818
62. Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C, Moulin P, Guiot Y, Feron O, Janssens S, Balligand JL (2004) Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 110:2666–2672. doi:10.1161/01.CIR.0000145608.80855.BC
63. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL (2001a) Upregulation of beta (3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103:1649–1655
64. Moniotte S, Vaerman JL, Kockx MM, Larrouy D, Langin D, Noirhomme P, Balligand JL (2001b) Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 33:2121–2133. doi:10.1006/jmcc.2001.1475
65. Nantel F, Bonin H, Emorine LJ, Zilberfarb V, Strosberg AD, Bouvier M, Marullo S (1993) The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol 43:548–555
66. Nedergaard J, Cannon B (2014) The browning of white adipose tissue: some burning issues. Cell Metab 20:396–407. doi:10.1016/j.cmet.2014.07.005
67. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Doring V, Kalmar P (1988) Increase in myocardial Gi-proteins in heart failure. Lancet 2:936–937
68. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch LA (2012) Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol 59:1979–1987. doi:10.1016/j.jacc.2011.12.046
69. Patterson AJ, Zhu W, Chow A, Agrawal R, Kosek J, Xiao RP, Kobilka B (2004) Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart. Crit Care Med 32:1041–1048
70. Pitcher JA, Freedman NJ, Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653–692. doi:10.1146/annurev.biochem.67.1.653
71. Porta S, Rinner I, Egger G, Rangetiner B, Sadjak A (1985) Enhancement of adrenaline plasma-levels shortens adrenaline half-life. Horm Metab Res 17:264–265. doi:10.1055/s-2007-1013513
72. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP Jr., Barsh GS, Bernstein D, Kobilka BK (1996) Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci U S A 93:7375–7380
73. Rona G (1985) Catecholamine cardiotoxicity. J Mol Cell Cardiol 17:291–306
74. Saeed M, Sommer O, Holtz J, Bassenge E (1982) Alpha-adrenoceptor blockade by phentolamine causes beta-adrenergic vasodilation by increased catecholamine release due to presynaptic alpha-blockade. J Cardiovasc Pharmacol 4:44–52
75. Schwinger RH, Munch G, Bolck B, Karczewski P, Krause EG, Erdmann E (1999) Reduced Ca(2+)- sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31:479–491
76. Skeberdis VA, Gendviliene V, Zablockaite D, Treinys R, Macianskiene R, Bogdelis A, Jurevicius J, Fischmeister R (2008) Beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest 118:3219–3227. doi:10.1172/JCI32519
77. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I, Mohmand W, Akbar R, Bahlmann F, Besler C, Schaefer A, Hilfiker-Kleiner D, Luscher TF, Balligand JL, Drexler H, Landmesser U (2011) Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. J Am Coll Cardiol 57:601–611. doi:10.1016/j.jacc.2010.09.037
78. Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper ME, Himms-Hagen J, Flier JS, Lowell BB (1995) Targeted disruption of the beta 3-adrenergic receptor gene. J Biol Chem 270:29483–29492
79. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82:1730–1736
80. Tagaya E, Tamaoki J, Takemura H, Isono K, Nagai A (1999) Atypical adrenoceptor-mediated relaxation of canine pulmonary artery through a cyclic adenosine monophosphate-dependent pathway. Lung 177:321–332
81. Trappanese DM, Liu Y, McCormick RC, Cannavo A, Nanayakkara G, Baskharoun MM, Jarrett H, Woitek FJ, Tillson DM, Dillon AR, Recchia FA, Balligand JL, Houser SR, Koch WJ, Dell’Italia LJ, Tsai EJ (2015) Chronic beta1-adrenergic blockade enhances myocardial beta3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective beta1-blocker therapy. Basic Res Cardiol 110:456. doi:10.1007/s00395-014-0456-3
82. Treinys R, Zablockaite D, Gendviliene V, Jurevicius J, Skeberdis VA (2014) Beta(3)-Adrenergic regulation of L-type Ca(2)(+) current and force of contraction in human ventricle. J Membr Biol 247:309–318. doi:10.1007/s00232-014-9635-2
83. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500–1508. doi:10.1056/NEJMoa0808718
84. Vij M, Drake MJ (2015) Clinical use of the beta3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome. Ther Adv Urol 7:241–248. doi:10.1177/1756287215591763
85. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerback S, Nuutila P (2009) Functional brown adipose tissue in healthy adults. N Engl J Med 360:1518–1525. doi:10.1056/NEJMoa0808949
86. Watts VL, Sepulveda FM, Cingolani OH, Ho AS, Niu X, Kim R, Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Rameau G, O’Rourke B, Kass DA, Barouch LA (2013) Anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation. J Mol Cell Cardiol 62:8–17. doi:10.1016/j.yjmcc.2013.04.025
87. Xiao RP, Ji X, Lakatta EG (1995) Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47:322–329
88. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP (2001) Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 98:1607–1612. doi:10.1073/pnas.98.4.1607